

Stabilis



Trastuzumab



Noms commerciaux

| | |
|--------------------|---|
| Herceptin | Allemagne, Arabie Saoudite, Argentine, Australie, Autriche, Belgique, Brésil, Canada, Chili, Colombie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Espagne, Etats Unis d'Amérique, Finlande, France, Grande Bretagne, Grèce, Hongrie, Iran, Irlande, Islande, Italie, Japon, Luxembourg, Malaisie, Maroc, Mexique, Norvège, Nouvelle Zélande, Pays bas, Pérou, Pologne, Portugal, Roumanie, Suède, Suisse, Turquie |
| Herclon | Pérou |
| Hertraz | Chili |
| Herzuma | Allemagne, Belgique, Espagne, Etats Unis d'Amérique, France, Grande Bretagne |
| Kanjinti | Allemagne, Belgique, Espagne, Grande Bretagne |
| Trastuzumab Baxter | Nouvelle Zélande |
| Trazimera | Grande Bretagne |



Stabilité des solutions

| | | | 21 mg/ml | 2-8°C | | 48 | | 3077 |
|--|--|--|---------------|---------|--|----|--|------|
| | | | 21 mg/ml | 23-27°C | | 3 | | 4271 |
| | | | 21 mg/ml | 4°C | | 30 | | 4493 |
| | | | 21 mg/ml | 2-8°C | | 28 | | 3113 |
| | | | 21 mg/ml | 2-5°C | | 90 | | 4191 |
| | | | mg/ml | <30°C | | 24 | | 3077 |
| | | | ? mg/ml | 2-8°C | | 30 | | 3077 |
| | | | 0,2 & 4 mg/ml | 2-8°C | | 42 | | 4754 |
| | | | 0,24 mg/ml | 2-8°C | | 7 | | 4163 |
| | | | 0,24 mg/ml | 30°C | | 24 | | 4163 |
| | | | 0,4 mg/ml | 2-8°C | | 28 | | 4194 |
| | | | 1 mg/ml | 2-8°C | | 28 | | 4194 |
| | | | 3,84 mg/ml | 2-8°C | | 7 | | 4163 |

| | | | | | | | | | |
|-----|--|-----------------|---------|--|-----|--|--|--|------|
| PVC | | 3,84 mg/ml | 30°C | | 24 | | | | 4163 |
| PVC | | 4 mg/ml | 2-8°C | | 28 | | | | 4194 |
| PE | | mg/ml | <30°C | | 24 | | | | 3077 |
| PE | | ? mg/ml | 2-8°C | | 30 | | | | 3077 |
| PE | | 0,32 mg/ml | 2-8°C | | 28 | | | | 4271 |
| PE | | 0,32 mg/ml | 23-27°C | | 28 | | | | 4271 |
| PE | | 0,56 mg/ml | 2-8°C | | 28 | | | | 4271 |
| PE | | 0,56 mg/ml | 23-27°C | | 28 | | | | 4271 |
| PE | | 4 mg/ml | 2-8°C | | 28 | | | | 4271 |
| PE | | 4 mg/ml | 23-27°C | | 28 | | | | 4271 |
| PP | | mg/ml | <30°C | | 24 | | | | 3077 |
| PP | | ? mg/ml | 2-8°C | | 30 | | | | 3077 |
| PP | | 0,4 mg/ml | 2-8°C | | 28 | | | | 3258 |
| PP | | 0,4 mg/ml | 2-8°C | | 28 | | | | 4194 |
| PP | | 0,4 mg/ml | 25°C | | 28 | | | | 3258 |
| PP | | 0,8 mg/ml | 4°C | | 180 | | | | 3343 |
| PP | | 1 mg/ml | 2-8°C | | 28 | | | | 4194 |
| PP | | 2,4 mg/ml | 4°C | | 180 | | | | 3343 |
| PP | | 4 mg/ml | 2-8°C | | 28 | | | | 3258 |
| PP | | 4 mg/ml | 2-8°C | | 28 | | | | 4194 |
| PP | | 4 mg/ml | 25°C | | 28 | | | | 3258 |
| POF | | 21 mg/ml | 2-8°C | | 63 | | | | 4649 |
| POF | | 0,2 & 4 mg/ml | 2-8°C | | 42 | | | | 4754 |
| POF | | 0,24 mg/ml | 2-8°C | | 7 | | | | 4163 |
| POF | | 0,24 mg/ml | 30°C | | 24 | | | | 4163 |
| POF | | 0,3 mg/ml | 2-8°C | | 21 | | | | 4649 |
| POF | | 0,3 mg/ml | 30°C | | 48 | | | | 4477 |
| POF | | 0,8 mg/ml | 18-22°C | | 180 | | | | 3386 |
| POF | | 0,8 mg/ml | 2-8°C | | 180 | | | | 3386 |
| POF | | 0,8 & 2,4 mg/ml | 2-5°C | | 90 | | | | 4191 |
| POF | | 0,8>>4 mg/ml | 2-8°C | | 76 | | | | 4649 |
| POF | | 0,3 mg/ml | 2-8°C | | 28 | | | | 4396 |
| POF | | 0,3 mg/ml | 30°C | | 28 | | | | 4396 |

| | | | | | | | | | |
|-----|--|-----------------|---------|--|-----|--|--|--|------|
| POF | | 0.8 & 2.4 mg/ml | 25°C | | 3 | | | | 4493 |
| POF | | 0.8 & 2.4 mg/ml | 4°C | | 90 | | | | 4493 |
| POF | | 2,4 mg/ml | 18-22°C | | 180 | | | | 3386 |
| POF | | 2,4 mg/ml | 2-8°C | | 180 | | | | 3386 |
| POF | | 3,8 mg/ml | 2-8°C | | 35 | | | | 4477 |
| POF | | 3,84 mg/ml | 2-8°C | | 7 | | | | 4163 |
| POF | | 3,84 mg/ml | 30°C | | 24 | | | | 4163 |
| POF | | 3.8 mg/ml | 2-8°C | | 28 | | | | 4396 |
| POF | | 3.8 mg/ml | 30°C | | 28 | | | | 4396 |
| EVA | | 0,2 & 4 mg/ml | 2-8°C | | 42 | | | | 4754 |
| | | 120 mg/ml | 2-8°C | | 48 | | | | 3647 |
| | | 120 mg/ml | 2-8°C | | 28 | | | | 2975 |
| | | 120 mg/ml | <30°C | | 6 | | | | 3647 |
| | | 120 mg/ml | 2-8°C | | 28 | | | | 2975 |
| | | 0,3 mg/ml | 2-8°C | | 21 | | | | 4649 |
| | | 0,8>>4 mg/ml | 2-8°C | | 76 | | | | 4649 |
| | | 0.4 >> 4 mg/ml | 2-8°C | | 28 | | | | 3849 |



Stabilité en mélange

| PVC | | 2.3 mg/ml | 30°C | | Pertuzumab : 2.7 mg/ml | | | 3366 |
|-----|--|-----------|------|--|------------------------|--|--|------|
| PVC | | 2.3 mg/ml | 5°C | | Pertuzumab : 2.7 mg/ml | | | 3366 |
| POF | | 1.5 mg/ml | 30°C | | Pertuzumab : 1.5 mg/ml | | | 3366 |
| POF | | 2.3 mg/ml | 30°C | | Pertuzumab : 2.7 mg/ml | | | 3366 |
| POF | | 2.3 mg/ml | 5°C | | Pertuzumab : 2.7 mg/ml | | | 3366 |



Facteur influençant la stabilité

| | | | | | |
|--|--|--|--|--|------|
| | | | | | 3077 |
|--|--|--|--|--|------|



Compatibilités

| | | | | |
|--|--|---|--|------|
| | | | | |
| | | Trastuzumab | | 3077 |
| | | Trastuzumab : 1,5 & 2,3 mg/ml Pertuzumab : 1,5 & 2,7 mg/ml | | 3366 |
| | | Trastuzumab Temocilline | | 2296 |



Voie d'administration



Bibliographie

| | Type | Source |
|------|-------------|---|
| 2296 | Laboratoire | Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017 |
| 2975 | Poster | Nalenz H, Schoenhammer K, Dietel E, Heynen S.R, Grauschoff U, Mahler H.C. In-Use stability of herceptin for subcutaneous injection with different administration materials. ESCP 2014 2014 |
| 3077 | Laboratoire | Trastuzumab (Herceptin®) – Summary of Product Characteristics Roche 2019 |
| 3113 | Ouvrage | Herceptin Compendium Suisse des médicaments 2010 |
| 3258 | Revue | Kaiser J, Krämer I. Physicochemical Stability of Diluted Trastuzumab Infusion Solutions in Polypropylene Infusion Bags. Int J Pharm Compound 2011 ; 15, 6 : 515-520. |
| 3343 | Poster | Vieillard V, da Silva R, Astier A, Paul M. Physicochemical stability of diluted trastuzumab solutions stored 6 months at 4°C. ECOP Congress, Budapest, Hungary 2012 |
| 3366 | Revue | Kwong Glover Z.W, Gennaro L, Yadav S, Demeule B, Wong P.Y, Sreedhara A. Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. J Pharm Sci 2012 ; DOI 10.1002 / jps.23403 |
| 3386 | Revue | Paul M, Vieillard V, Da Silva Lemos R, Escalup L, Astier A. Long-term physico-chemical stability of diluted trastuzumab. Int J Pharm 2013 ; 448: 101-104. |
| 3647 | Laboratoire | Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics Roche 2019 |
| 3849 | Revue | Pabari R.M, Ryan B, Ahmad W, Ramtoola Z. Physical and structural stability of the monoclonal antibody, trastuzumab (Herceptin®), intravenous solutions. Curr Pharm Biotech 2013 ; 14, 2: 220-225. |
| 4163 | Revue | Nalenz H, K?pf E, Dietel E. Prolonged In-Use Stability of Reconstituted Herceptin in Commercial Intravenous Bags. Int J Pharm Compound 2018 22;5:417-423 |

| | | |
|------|-------|---|
| 4191 | Revue | Vieillard V, Astier A, Paul M. Extended stability of a biosimilar of trastuzumab (CT-P6) after reconstitution in vials, dilution in polyolefin bags and storage at various temperatures. GaBI Journal 2018 |
| 4194 | Revue | Kim S.J, Lee J.W, Kang H.Y, Kim S.Y, Shin Y.K, Kim K.W, Oh J.S, Lim K.J, Kim J.Y. In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. Bio Drugs 2018 32;619-625 |
| 4271 | Revue | Yun J, Kim J, Chung J, Hwang S-J, Park S-J. Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties Adv Ther 2019 |
| 4396 | Revue | Lueras A, Polozova A, Asbury D, Hippenmeyer J, Litowski J, Goss M, Breslin P, Crampton S. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentrations and stress conditions. GaBI Journal 2020 ; 9, 1: |
| 4477 | Revue | Crampton S, Polozova A, Asbury D, Lueras A, Breslin P, Hippenmeyer J, Litkowski J, Goss M. Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. GaBI Journal 2020 ; 9, 1: 5-13. |
| 4493 | Revue | Le Guyader G, Vieillard V, Paul M. Physicochemical stability study of MYL-1401O, a biosimilar of trastuzumab, following a transient temperature excursion. J Oncol Pharm Practice 2020 |
| 4649 | Revue | Davies L, Milligan K, Corris M, Clarke I, Dwyer P, Lee S-E, Teraoka J, Crouse-Zeineddin J, Hippenmeyer J. Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices. GaBI Journal 2021 ; 10, 4 |
| 4754 | Revue | Weiser S, Burns C, Zartler E Physicochemical stability of PF-05280014 (trastuzumab-qyyp; Trazimera™), a trastuzumab biosimilar, under extended in-use conditions. J Oncol Pharm Practice 2023 ;29,3: |



Dictionnaire

| | | | |
|--|---------------------------------|--|----------------------------------|
| | Anticancéreux | | Injectable |
| | Noms commerciaux | | Stabilité des solutions |
| | Contenant | | Molécule |
| | Concentration | | Température |
| | Conservation | | Durée de stabilité |
| | Biosimilaire | | Données conflictuelles |
| | Bibliographie | | Verre |
| | Eau pour préparation injectable | | Non précisée |
| | Heure | | A l'abri de la lumière |
| | Jour | | Eau ppi + bactériostatique |
| | Flacon entamé | | Polyvinyl chlorure |
| | Chlorure de sodium 0,9% | | Lumière |
| | Polyéthylène | | Polypropylène |
| | Avec ou sans lumière | | Polyolefine |
| | Ethylène vinyl acétate | | Seringue polypropylène |
| | Aucun | | Seringue polycarbonate |
| | Elastomère en polyisoprène | | Non précisé |
| | Stabilité en mélange | | Solvant |
| | Molécule | | Facteur influençant la stabilité |
| | Glucose 5% | | Provoque |
| | Dégénération | | Compatibilités |
| | Incompatible | | Compatible |
| | Incompatibilité non précisée | | Voie d'administration |
| | Perfusion intraveineuse | | Sous cutanée |
| | Bibliographie | | Dictionnaire |